| New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness H Yang, SQ Liang, RA Schmid, RW Peng Frontiers in oncology 9, 953, 2019 | 140 | 2019 |
| EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China J Xu, B Jin, T Chu, X Dong, H Yang, Y Zhang, D Wu, Y Lou, X Zhang, ... Lung cancer 96, 87-92, 2016 | 103 | 2016 |
| Surgical therapy for bilateral multiple primary lung cancer H Yang, Y Sun, F Yao, K Yu, H Gu, B Han, H Zhao The Annals of Thoracic Surgery 101 (3), 1145-1152, 2016 | 81 | 2016 |
| Prophylactic cranial irradiation for patients with surgically resected small cell lung cancer J Xu, H Yang, X Fu, B Jin, Y Lou, Y Zhang, X Zhang, H Zhong, H Wang, ... Journal of Thoracic Oncology 12 (2), 347-353, 2017 | 68 | 2017 |
| Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma T Zhang, B Sun, C Zhong, K Xu, Z Wang, P Hofman, T Nagano, A Legras, ... Translational lung cancer research 10 (4), 1857, 2021 | 64 | 2021 |
| Single-stage bilateral pulmonary resections by video-assisted thoracic surgery for multiple small nodules F Yao, H Yang, H Zhao Journal of Thoracic Disease 8 (3), 469, 2016 | 55 | 2016 |
| Multi-scale integrative analyses identify THBS2+ cancer-associated fibroblasts as a key orchestrator promoting aggressiveness in early-stage lung adenocarcinoma H Yang, B Sun, L Fan, W Ma, K Xu, SRR Hall, Z Wang, RA Schmid, ... Theranostics 12 (7), 3104, 2022 | 54 | 2022 |
| HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer H Yang, SQ Liang, D Xu, Z Yang, TM Marti, Y Gao, GJ Kocher, H Zhao, ... Oncogenesis 8 (9), 45, 2019 | 54 | 2019 |
| CD73, tumor plasticity and immune evasion in solid cancers H Yang, F Yao, PF Davis, ST Tan, SRR Hall Cancers 13 (2), 177, 2021 | 53 | 2021 |
| IL-20RB mediates tumoral response to osteoclastic niches and promotes bone metastasis of lung cancer Y He, W Luo, Y Liu, Y Wang, C Ma, Q Wu, P Tian, D He, Z Jia, X Lv, ... The Journal of Clinical Investigation 132 (20), 2022 | 52 | 2022 |
| mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer SQ Liang, ED Bührer, S Berezowska, TM Marti, D Xu, L Froment, H Yang, ... Oncogene 38 (5), 622-636, 2019 | 52 | 2019 |
| Resected tracheal adenoid cystic carcinoma: improvements in outcome at a single institution H Yang, F Yao, J Tantai, Y Zhao, Q Tan, H Zhao The Annals of Thoracic Surgery 101 (1), 294-300, 2016 | 52 | 2016 |
| Preoperative peripheral blood neutrophil-to-lymphocyte ratios (NLR) and platelet-to-lymphocyte ratio (PLR) related nomograms predict the survival of patients with limited-stage … C Chen, H Yang, D Cai, L Xiang, W Fang, R Wang Translational lung cancer research 10 (2), 866, 2021 | 48 | 2021 |
| Multienzyme‐Mimicking LaCoO3 Nanotrigger for Programming Cancer‐Cell Pyroptosis K Xu, M Chang, Z Wang, H Yang, Y Jia, W Xu, B Zhao, Y Chen, F Yao Advanced materials 35 (35), 2302961, 2023 | 45 | 2023 |
| Multicenter, prospective, observational study of a novel technique for preoperative pulmonary nodule localization L Fan, H Yang, LM Yu, Z Wang, J Ye, Y Zhao, D Cai, H Zhao, F Yao The Journal of thoracic and cardiovascular surgery 160 (2), 532-539. e2, 2020 | 44 | 2020 |
| Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma H Yang, D Xu, RA Schmid, RW Peng Therapeutic advances in medical oncology 12, 1758835920971421, 2020 | 40 | 2020 |
| Clinical outcomes of surgically resected combined small cell lung cancer: a two-institutional experience C Zhang, H Yang, H Zhao, B Lang, X Yu, P Xiao, X Zhang Journal of thoracic disease 9 (1), 151, 2017 | 37 | 2017 |
| Endoplasmic reticulum stress signaling as a therapeutic target in malignant pleural mesothelioma D Xu, H Yang, Z Yang, S Berezowska, Y Gao, SQ Liang, TM Marti, ... Cancers 11 (10), 1502, 2019 | 36 | 2019 |
| NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma H Yang Cancers 13 (7), 1561, 2021 | 35 | 2021 |
| CRISPR screening identifies WEE1 as a combination target for standard chemotherapy in malignant pleural mesothelioma D Xu, SQ Liang, H Yang, R Bruggmann, S Berezowska, Z Yang, TM Marti, ... Molecular cancer therapeutics 19 (2), 661-672, 2020 | 35 | 2020 |
